BIOif 365 hold, going to 424
an upward trend in the prices of an industry's stocks or the overall rise in broad market indices, characterized by high investor confidence
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−65.00 USD
−1.84 B USD
2.57 B USD
19.20 M
About Bio-Rad Laboratories, Inc.
Sector
Industry
CEO
Norman D. Schwartz
Website
Headquarters
Hercules
Founded
1952
FIGI
BBG000DY28W5
Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Bio-Rad Laboratories SELL Short-Term Momentum (< 3 Months)Bio-Rad Laboratories shows potential for a SELL based on short-term momentum. Target price is 255.00 USD. Time horizon for this trade is up to 3 months.
BIO: some upside potential?A price action above 340 supports a bullish trend direction.
Bullish confirmation for a break above 354.00.
The target price is set at 397.00.
The stop-loss price is set at 322 (its 50% Fibonacci retracement level).
Breaking above its 200-day might trigger further upside potential.
Remains a risky t
BIO: some upside?A price action above 448 supports a bullish trend direction.
The stock is testing its 200-day simple moving average. A change in sentiment towards bullish might occur.
Further bullish confirmation for a break above 478.
Profit target is at 498.
Stop-loss is at 443.
Type of a broadening top pattern i
BIO: some waterfall price action?A price action below 460 supports a bearish trend direction.
The stock is testing its 200-day simple moving average. A confirmed cross below this level will change the sentiment to a full-blown bearish sentiment.
Increase short exposure for a break below 450.
The target price is set at 420.
Stop-los
BIO | Medical Device Co | Good EntryBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures,
BIO // He must break the enemyHe must break the enemy.
Let's look for closure where I specified with X.
The targets were determined according to Fibonacci.
$BIO with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $BIO after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 90%.
$BIO - Is in a neutral pH today.$BIO had the bears winning for the last year, but looks like Bulls are starting to pile up and a tag of war is on the verge. NYSE:BIO
$BIO with a Neutral outlook following its earnings #Stocks The PEAD projected a Neutral outlook for $BIO after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 33.33%.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
BIO5368765
Bio-Rad Laboratories, Inc. 3.7% 15-MAR-2032Yield to maturity
5.92%
Maturity date
Mar 15, 2032
BIO5368763
Bio-Rad Laboratories, Inc. 3.3% 15-MAR-2027Yield to maturity
4.96%
Maturity date
Mar 15, 2027
See all BIO bonds
Related stocks
Frequently Asked Questions
The current price of BIO is 248.85 USD — it has increased by 1.58% in the past 24 hours. Watch Bio-Rad Laboratories, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Bio-Rad Laboratories, Inc. stocks are traded under the ticker BIO.
BIO stock has risen by 0.85% compared to the previous week, the month change is a −3.53% fall, over the last year Bio-Rad Laboratories, Inc. has showed a −13.00% decrease.
We've gathered analysts' opinions on Bio-Rad Laboratories, Inc. future price: according to them, BIO price has a max estimate of 409.00 USD and a min estimate of 270.00 USD. Watch BIO chart and read a more detailed Bio-Rad Laboratories, Inc. stock forecast: see what analysts think of Bio-Rad Laboratories, Inc. and suggest that you do with its stocks.
BIO stock is 6.07% volatile and has beta coefficient of 0.53. Track Bio-Rad Laboratories, Inc. stock price on the chart and check out the list of the most volatile stocks — is Bio-Rad Laboratories, Inc. there?
Today Bio-Rad Laboratories, Inc. has the market capitalization of 6.97 B, it has decreased by −3.22% over the last week.
Yes, you can track Bio-Rad Laboratories, Inc. financials in yearly and quarterly reports right on TradingView.
Bio-Rad Laboratories, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
BIO earnings for the last quarter are 2.90 USD per share, whereas the estimation was 2.87 USD resulting in a 1.10% surprise. The estimated earnings for the next quarter are 1.81 USD per share. See more details about Bio-Rad Laboratories, Inc. earnings.
Bio-Rad Laboratories, Inc. revenue for the last quarter amounts to 667.50 M USD, despite the estimated figure of 679.29 M USD. In the next quarter, revenue is expected to reach 573.26 M USD.
BIO net income for the last quarter is −715.80 M USD, while the quarter before that showed 653.17 M USD of net income which accounts for −209.59% change. Track more Bio-Rad Laboratories, Inc. financial stats to get the full picture.
No, BIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 24, 2025, the company has 7.7 K employees. See our rating of the largest employees — is Bio-Rad Laboratories, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bio-Rad Laboratories, Inc. EBITDA is 524.27 M USD, and current EBITDA margin is 19.63%. See more stats in Bio-Rad Laboratories, Inc. financial statements.
Like other stocks, BIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bio-Rad Laboratories, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bio-Rad Laboratories, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bio-Rad Laboratories, Inc. stock shows the sell signal. See more of Bio-Rad Laboratories, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.